Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

2012680 citationsJournal Articlebronze Open Access

Authors

Tina Green · Hospital South West Jutland

Ken H. Young · Hospital South West Jutland

Carlo Visco · Hospital South West Jutland

Zijun Y. Xu‐Monette · Hospital South West Jutland

Attilio Orazi · Hospital South West Jutland

Ronald S. Go · Hospital South West Jutland

Ole Nielsen

Abstract

The immunohistochemical DHS defined a large subset of DLBCLs with double-hit biology and was strongly associated with poor outcome in patients treated with R-CHOP.

Topics & Keywords

Lymphoma Diagnosis and Treatment Viral-associated cancers and disorders CAR-T cell therapy research

Publication Details

Published in: Journal of Clinical Oncology

Volume 30, Issue 28, pp. 3460-3467

DOI: 10.1200/jco.2011.41.4342

Field-Weighted Citation Impact: 38.16

Command Palette

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Authors

Abstract

Topics & Keywords

Publication Details